Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/96264
Title: Effectivity of pazopanib treatment in orthotopic models of human testicular germ cell tumors
Author: Juliachs Milà, Mercè
Vidal-Bel, August
García del Muro Solans, Xavier
Piulats, Josep M.
Condom i Mundó, Enric
Casanovas i Casanovas, Oriol
Graupera, Mariona
Germà Lluch, José Ramón
Villanueva Garatachea, Alberto
Viñals Canals, Francesc
Keywords: Càncer
Malalties del testicle
Tumors
Cisplatí
Cancer
Testis diseases
Tumors
Cisplatin
Issue Date: 10-Aug-2013
Publisher: BioMed Central
Abstract: Background: Cisplatin (CDDP) resistance in testicular germ cell tumors (GCTs) is still a clinical challenge, and one associated with poor prognosis. The purpose of this work was to test pazopanib, an anti-tumoral and anti-angiogenic multikinase inhibitor, and its combination with lapatinib (an anti-ErbB inhibitor) in mouse orthotopic models of human testicular GCTs. Methods: We used two different models of human testicular GCTs orthotopically grown in nude mice; a CDDP-sensitive choriocarcinoma (TGT38) and a new orthotopic model generated from a metastatic GCT refractory to first-line CDDP chemotherapy (TGT44). Nude mice implanted with these orthotopic tumors were treated with the inhibitors and the effect on tumoral growth and angiogenesis was evaluated. Results: TGT44 refractory tumor had an immunohistochemical profile similar to the original metastasis, with characteristics of yolk sac tumor. TGT44 did not respond when treated with cisplatin. In contrast, pazopanib had an anti-angiogenic effect and anti-tumor efficacy in this model. Pazopanib in combination with lapatinib in TGT38, an orthotopic model of choriocarcinoma had an additive effect blocking tumor growth. Conclusions: We present pazopanib as a possible agent for the alternative treatment of CDDP-sensitive and CDDP-refractory GCT patients, alone or in combination with anti-ErbB therapies.
Note: Reproducció del document publicat a: http://dx.doi.org/10.1186/1471-2407-13-382
It is part of: BMC Cancer, 2013, vol. 13, num. 382
Related resource: http://dx.doi.org/10.1186/1471-2407-13-382
URI: http://hdl.handle.net/2445/96264
ISSN: 1471-2407
Appears in Collections:Articles publicats en revistes (Patologia i Terapèutica Experimental)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
638374.pdf1.05 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons